BUY Mankind Pharma Limited — Geojit Financial Services
byGeojit Financial ServicesHorizon: NA (inferred 1 year)26 Nov 2025via Institutional / Brokerage Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Mankind Pharma announced its Q4FY26 and FY26 financial results. Revenue increased by 11.8% YoY to INR 3,443 Cr in Q4FY26, with Adj. EBITDA margin at 27.1%. FY26 revenue grew 17.0% to INR 14,278 Cr.
NSE · Press Release·19 May · today
Mankind Pharma reported Q4FY26 & FY26 financial results. Revenues increased 11.8% YoY to INR 3,443 Cr in Q4FY26 and 17.0% YoY to INR 14,278 Cr in FY26. Adj. EBITDA margin was 27.1% in Q4FY26.
BSE · Company Update·19 May · today
1 other SEBI-registered advisor has an active long-term BUY call on this stock
Advisor consensus · same horizon·29 Apr · 3w ago
Please find attached Audited Financail Results for the quarter and year ended March 31, 2026
BSE · Board Meeting·19 May · today
Mankind Pharma Limited has received credit ratings from CARE Ratings Limited for its long-term/short-term bank facilities amounting to ₹1,000 crore. The ratings assigned are CARE AA+ (Stable) for long
NSE · Credit Rating- New·22 Apr · 4w ago
Mankind Pharma Ltd has attached an intimation regarding credit ratings assigned by CARE Ratings Limited.
BSE · Company Update·22 Apr · 4w ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Mankind Pharma
- BUY — Rajesh Satpute7 Oct 2026 · Next day · target ₹2,550 · SL hit
- BUY — Swati Hotkar, Nirmal Bang Securities7 Oct 2026 · Same day · target ₹2,580 · Expired
- SELL — Macquarie7 Oct 2026 · ~1 year · target ₹2,200 · Target hit
- BUY — Vishvesh Chauhan, ChaseAlpha30 Sept 2026 · ~2 weeks · target ₹2,640 · SL hit
- BUY — Raja Venkatraman30 Sept 2026 · ~3 months · target ₹2,800 · SL hit
More from Geojit Financial Services
- BUY Tata Consultancy Services14 Oct 2026 · ~1 year · target ₹2,530 · Target hit
- BUY Apex Frozen Foods6 Oct 2026 · ~1 year · target ₹430 · Active
- BUY Ashok Leyland29 Sept 2026 · ~1 year · target ₹179 · Active
- BUY Sun Pharmaceutical Industries21 Sept 2026 · ~1 year · target ₹2,070 · Active
- BUY Tata Motors17 Sept 2026 · ~1 year · target ₹482 · Active

